However, up to 30% of IBD patients appear to be primary non-responders who do not clinically benefit from anti-TNF-α induction therapy, while another 30–40% lose response during the first year of the treatment, leading to the need to increase their dosage or switch to another biologic agent11. Here, TNF is linked to irritable bowel syndrome.